GlassScriptPhysician profile
Neil S Baman
NPI 1285847053
$4,782.78
in general payments reported to CMS, 2019-2025
19 companies · $505 in 2025
The $505 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,947 · 2020: $336 · 2021: $1,548 · 2022: $39.26 · 2023: $244 · 2024: $163 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,624.62 | 2019-2025 | Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $586.23 | 2019-2021 | |
| Genzyme Corporation | $394.15 | 2019-2024 | |
| Genentech USA, INC. | $362.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $333.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $314.91 | 2019-2025 | Dupixent |
| Csl Behring | $240.92 | 2023-2025 | Haegarda, Andembry |
| Teva Pharmaceuticals USA, INC. | $200.41 | 2021 | |
| Kaleo, INC. | $132.33 | 2019-2021 | |
| Octapharma USA, INC. | $130.64 | 2019 | |
| Optinose US, INC. | $106.81 | 2019-2021 | |
| Covis Pharma Gmbh | $88.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.08 | 2021 | |
| Grifols USA, LLC | $69.20 | 2023 | Prolastin-C Liquid, Xembify |
| Pharming Healthcare, INC. | $48.22 | 2020-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $22.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.10 | 2019 | |
| Circassia INC. | $16.95 | 2019 | |
| Phadia US INC. | $13.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Baman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.